Business context and reporting period
Filing identity discrepancy: The supplied filing is Cerulean Pharma Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014. It does not identify Dare Bioscience, Inc.; verify that this is the intended filing.
Cerulean was a clinical-stage oncology company developing nanopharmaceutical candidates, including CRLX101 and CRLX301. It reported no product-sales revenue and described itself as a development-stage company.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | $47,000 | $0 |
| Research and development | $1.495 million | $3.479 million |
| General and administrative | $1.510 million | $1.972 million |
| Operating loss | $2.958 million | $5.451 million |
| Net loss | $2.914 million | $5.572 million |
| Net loss per share, basic and diluted | $3.70 | $9.09 |
| Net cash used in operating activities | $3.666 million | $4.602 million |
Revenue in Q1 2014 came from material transfer agreements, not product sales. Net loss improved 48% year over year, primarily as operating expenses declined; R&D fell 57% and G&A fell about 23%. The company attributed lower R&D mainly to winding down a CRLX101 NSCLC trial and earlier completion of CRLX301 development work. No meaningful operating margin was reported; the business remained loss-making.
At March 31, 2014, cash and cash equivalents were $8.468 million, current assets $11.501 million, and current liabilities $24.180 million. Total assets were $11.854 million, while stockholders’ deficit was $97.038 million and accumulated development-stage deficit was $101.353 million. Loan principal outstanding was approximately $5.9 million; the balance sheet also showed $17.324 million of shareholder convertible notes. The notes bore 7% interest and converted into common stock after the IPO. The Lighthouse loan bore 8.25% interest and was secured by substantially all assets other than intellectual property.
Q1 financing activities provided $6.650 million, principally from $8.5 million of convertible notes, offset by debt repayments and deferred financing costs. Cash increased $2.980 million during the quarter. Interest expense was $461,000; reported results also included a $504,000 noncash gain from the decline in the preferred-warrant liability.
Material developments and outlook
- After quarter-end, the company completed its IPO on April 15, 2014, selling 8.5 million shares at $7 per share, and sold another 1,069,715 shares through a partial over-allotment exercise on May 7. The filing gives differing net-proceeds figures: approximately $60.1 million in the use-of-proceeds discussion, $61.5 million estimated subsequent to March 31 in MD&A, and $53.2 million plus $7.0 million in the financial-statement note. Reconciliation is not clear from the filing text.
- At the IPO, preferred stock and convertible notes converted into common shares; warrants were converted and the warrant liability reclassified to additional paid-in capital. The filing reports 20,123,013 common shares outstanding as of May 19, 2014.
- Management planned a randomized Phase 2 CRLX101 trial with Avastin for relapsed renal cell carcinoma in the second half of 2014, and intended to begin a Phase 1 CRLX301 trial by year-end 2014. Further CRLX101 trials in ovarian and rectal cancer were contingent on clinical results.
- Management expected R&D and public-company costs to rise and stated that the IPO proceeds and cash would fund operations for at least 12 months in the liquidity discussion. A risk-factor discussion separately estimated at least 18 months of funding, while also warning that estimates depend on assumptions and additional trials could require more capital. The filing says additional funding would be needed for certain planned trials and longer-term development.
- Key risks include clinical failure—the prior Phase 2 CRLX101 NSCLC trial failed its primary overall-survival endpoint—uncertain early investigator-sponsored trial results, regulatory and safety uncertainty, manufacturing delays (including a prior CRLX301 batch-contamination issue), dependence on third parties, and financing needs. Calando Pharmaceuticals, a licensor, entered Chapter 7 bankruptcy in March 2014, creating potential license-related risk.
Important facts for investors to verify
- Confirm the intended issuer: the filing is for Cerulean Pharma Inc., not Dare Bioscience, Inc.
- Reconcile reported IPO net proceeds and clarify which figure reflects actual proceeds available to the company.
- Compare the stated 12-month and 18-month cash-runway estimates and assess assumptions, expected burn, and trial funding needs.
- Verify post-IPO share count, conversion terms and dilution from preferred shares, notes, warrants, options, and equity plans.
- Track CRLX101 and CRLX301 trial timelines, outcomes, manufacturing readiness, and any required additional capital.
- Assess the continuing status and enforceability of licensed intellectual property following Calando’s bankruptcy.